Kolexia
Renault Patrick Pneumologie
Renault Patrick
Pneumologie
Centre Hospitalier de Pau
Pau, France
56 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Effets secondaires indésirables des médicaments Récidive tumorale locale Carcinome épidermoïde Myosite Méningite Carcinomes

Collaborateurs

Voir plus
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France
Audigier-Valette Clarisse
Audigier-Valette Clarisse
Centre Hospitalier Toulon, Toulon, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Molinier Olivier
Molinier Olivier
Centre Hospitalier du Mans, Le Mans, France

Industries

Voir plus
AstraZeneca
16 collaboration(s)
Dernière en 2023
MSD
11 collaboration(s)
Dernière en 2022
BMS
10 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
REAL-MOOV-LUNG: Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG
Essai Clinique (Institut Curie)   19 décembre 2023
1420P Real-life management of octogenarians with NSCLC in a French nationwide cohort
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Ultimate: Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   10 mars 2023
132P 20 years of real life nationwide epidemiological data on lung cancer in non-academic French public hospitals: KBP-2020-CPHG compared to 2000 and 2010 studies
European Lung Cancer Congress (ELCC) 2022, 30 March-2 April 2022   01 avril 2022
LADIE: Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 janvier 2021
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
The Lancet. Oncology   23 septembre 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
European journal of cancer (Oxford, England : 1990)   06 septembre 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
European journal of cancer (Oxford, England : 1990)   08 avril 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research   06 mars 2020
Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review.
La Revue de medecine interne   23 janvier 2020